Nanrilkefusp alfa (SOT101), an IL-15 receptor βγ superagonist, as a single agent or with anti-PD-1 in patients with advanced cancers
Stéphane Champiat(The University of Texas MD Anderson Cancer Center), Aurélien Marabelle(Institut Gustave Roussy)
Cited by 5
Related Papers
Intratumoural administration and tumour tissue targeting of cancer immunotherapies
|Nature Reviews Clinical Oncology|2021|469
Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade
|Cell Research|2019|246
Phase 2 study of pembrolizumab in advanced small-cell lung cancer (SCLC): KEYNOTE-158.
|Journal of Clinical Oncology|2018|208
Predictors of responses to immune checkpoint blockade in advanced melanoma
|Nature Communications|2017|201
How to manage patients with corticosteroids in oncology in the era of immunotherapy?
|European Journal of Cancer|2020|87